Combination of Rivaroxaban And Aspirin Improves CV Outcomes: COMPASS Trial
Cardiovascular diseases are the leading cause of death globally. Though new medications and the use of effective secondary prevention strategies, 5% to 10% of patients with cardiovascular disease have recurrent events each year with worst outcomes mostly being cardiac death. Rivaroxaban is used to prevent blood clots from forming due to atrial fibrillation however its known to cause major risk of bleeding when given higher doses, hence its safety is a question mark for its regular use.
A new trial COMPASS by Dr. John W. Eikelboom, M.B.B.S. and team revealed that patients with stable atherosclerotic vascular disease, those assigned to rivaroxaban (2.5 mg twice daily) plus aspirin had better cardiovascular outcomes and more major bleeding events than those assigned to aspirin alone. 5 mg of rivaroxaban twice daily alone did not help any better than aspirin alone and resulted in more major bleeding events.
For more details, checkout the full story on link below:
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement/treatment or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2024 Minerva Medical Treatment Pvt Ltd